Comment on: Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study

J Antimicrob Chemother. 2023 Jul 5;78(7):1808-1809. doi: 10.1093/jac/dkad151.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Letter
  • Kommentar

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • HIV Infections* / drug therapy
  • Heterocyclic Compounds, 3-Ring / adverse effects
  • Humans
  • Oxazines / therapeutic use
  • Pyridones / therapeutic use

Substances

  • dolutegravir
  • Anti-HIV Agents
  • Oxazines
  • Heterocyclic Compounds, 3-Ring
  • Pyridones